Preferred Primary Care Physicians | Pittsburgh, PA

Research site

(Unclaimed)

Location

140 Curry Hollow Road, Suite 3, Pittsburgh, Pennsylvania, United States of America

Site insights

Top conditions

Top treatments

Relamorelin

Atogepant

Linaclotide

Erenumab

Semaglutide

Galcanezumab

Eluxadoline

ABP-450

Bococizumab

Tirzepatide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 59 total trials

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic o...

Active, not recruiting

Chronic Migraine

Episodic Migraine

Drug: Atogepant 60 mg

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The st...

Enrolling

Diabetes Mellitus, Type 2

Drug: Trizepatide

Drug: NNC0519-0130

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study interventi...

Invitation-only

Irritable Bowel Syndrome

Drug: 25mg Eluxadoline

Drug: 100mg Eluxadoline

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD-1)

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling

Episodic Migraine

Drug: Galcanezumab

Drug: Placebo

Locations recently updated

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting

Type 2 Diabetes Mellitus

Drug: Tirzepatide

Drug: Dulaglutide

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling

Obesity

Drug: Placebo

Drug: survodutide

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9-valent human papillomavirus (9vHPV) vaccine in men 20 to 45...

Active, not recruiting

Papillomavirus Infections

Biological: 9vHPV Vaccine

Other: Placebo (Saline for Injection)

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (OASIS(EM))

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling

Migraine

Drug: Erenumab Dose 3

Drug: Erenumab Dose 1

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (OASIS(CM))

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling

Migraine

Drug: Erenumab Dose 2

Drug: Erenumab Dose 3

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatmen...

Active, not recruiting

Migraine

Drug: Placebo comparator dosing

Drug: Rimegepant 75mg every other day dosing

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes (REVITALIZE 1)

The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints f...

Enrolling

Type 2 Diabetes

Device: Duodenal Mucosal Resurfacing (Sham)

Device: Duodenal Mucosal Resurfacing (DMR)

Status recently updated

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension

This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypert...

Enrolling

Invitation-only

Hypertension

Drug: lorundrostat

Drug: Placebo

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D)...

Enrolling

Irritable Bowel Syndrome

Drug: Eluxadoline

Drug: Placebo